Osiris Therapeutics (Osiris Therapeutics) Capital Expenditure : $-0.24 Mil (TTM As of Dec. 2018)

View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Osiris Therapeutics's cash flow for capital expenditures for the three months ended in Dec. 2018 was $-0.1 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.24 Mil.

Osiris Therapeutics Capital Expenditure Historical Data

The historical data trend for Osiris Therapeutics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Capital Expenditure Chart

Osiris Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Capital Expenditure

Get a 7-Day Free Trial

-1.12

-0.93

-1.35

-2.01

-0.24

Osiris Therapeutics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Capital Expenditure	Get a 7-Day Free Trial															-1.29	-0.10	-0.03	-0.05	-0.06

Osiris Therapeutics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

Osiris Therapeutics (Osiris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707

Website

http://www.osiris.com

Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.

Executives

Reinhart Charles A. Iii	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang	officer: Chief Financial Officer	ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal	officer: Chiel Legal Officer
Linda Palczuk	officer: President & CEO	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White	director
Thomas J Knapp	director	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr	officer: Principal Accounting Officer
C Randal Mills	director, officer: President & CEO	18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes	director
Stephen W Potter	officer: Senior Vice President	7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill	director